Iterum Therapeutics Plc (ITRM) Misses Q3 EPS by 5c

Iterum Therapeutics Plc (NASDAQ: ITRM) reported Q3 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $390 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Iterum Therapeutics Plc (ITRM) click here.

You May Also Be Interested In

• American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
• Aurania closes C$1.26M private placement in two tranches
• Zeus North America Mining signs option for Idaho mining claims